Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Annals of the Rheumatic Diseases
|
March 1, 1994
Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to laminin
D E Cohen, L D Kaufman, A A Varma, et al.
The Laryngoscope
|
March 1, 1992
Is outpatient tonsillectomy appropriate for young children?
L W Tom, R M DeDio, D E Cohen, et al.
American Journal of Physiology. Cell Physiology
|
April 5, 2001
Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins
P G Frank, F Galbiati, D Volonte, et al.
Journal of Viral Hepatitis
|
October 6, 2015
Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects
J F Waring, E O Dumas, S Abel, et al.
Catheterization and Cardiovascular Diagnosis
|
January 1, 1996
Cocktail attenuation of rotational ablation flow effects (CARAFE) study: pilot
B M Cohen, V J Weber, R R Blum, et al.
Cutis
|
July 1, 1994
New York University therapeutic roundtable: a panel of experts answer questions on the treatment of challenging cases
J L Shupack, N Kanof, L P Stolman, et al.
Hepatology (Baltimore, Md.)
|
May 9, 2001
Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi
J Shoda, K Oda, H Suzuki, et al.
Journal of Lipid Research
|
February 22, 2001
Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice
P Mardones, V Quiñones, L Amigo, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
December 14, 2011
MicroRNAs in metabolism and metabolic diseases
V Rottiers, S H Najafi-Shoushtari, F Kristo, et al.
Journal of Viral Hepatitis
|
August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S D Shafran, D Shaw, M Charafeddine, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Annals of the Rheumatic Diseases
|
March 1, 1994
Anti-laminin autoantibodies in collagen vascular diseases: the use of adequate controls in studies of autoimmune responses to laminin
D E Cohen, L D Kaufman, A A Varma, et al.
The Laryngoscope
|
March 1, 1992
Is outpatient tonsillectomy appropriate for young children?
L W Tom, R M DeDio, D E Cohen, et al.
American Journal of Physiology. Cell Physiology
|
April 5, 2001
Influence of caveolin-1 on cellular cholesterol efflux mediated by high-density lipoproteins
P G Frank, F Galbiati, D Volonte, et al.
Journal of Viral Hepatitis
|
October 6, 2015
Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects
J F Waring, E O Dumas, S Abel, et al.
Catheterization and Cardiovascular Diagnosis
|
January 1, 1996
Cocktail attenuation of rotational ablation flow effects (CARAFE) study: pilot
B M Cohen, V J Weber, R R Blum, et al.
Cutis
|
July 1, 1994
New York University therapeutic roundtable: a panel of experts answer questions on the treatment of challenging cases
J L Shupack, N Kanof, L P Stolman, et al.
Hepatology (Baltimore, Md.)
|
May 9, 2001
Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi
J Shoda, K Oda, H Suzuki, et al.
Journal of Lipid Research
|
February 22, 2001
Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice
P Mardones, V Quiñones, L Amigo, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
December 14, 2011
MicroRNAs in metabolism and metabolic diseases
V Rottiers, S H Najafi-Shoushtari, F Kristo, et al.
Journal of Viral Hepatitis
|
August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S D Shafran, D Shaw, M Charafeddine, et al.
Page
of 9